Please assess the completion status of the following clinical trial:

Trial Title: Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to complete questionnaires by themselves or with assistance~* Planned paclitaxel at a dose of 80 mg/m2 IV given, in the adjuvant breast cancer (postoperative or neo-adjuvant) setting, every week for a planned course of 12 weeks without any other concurrent cytotoxic chemotherapy (trastuzumab and/or other antibody and/or small molecule treatment is allowed, except for PARP inhibitors)~* Life expectancy \> 6 months~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Negative pregnancy test (serum or urine) done =\< 7 days prior to registration, for women of childbearing potential only (determined per clinician discretion)~Exclusion Criteria:~* Any of the following:~  * Pregnant women~ * Nursing women~ * Men or women of childbearing potential who are unwilling to employ adequate contraception~* Previous diagnosis of diabetic neuropathy or peripheral neuropathy from any cause~* History of allergic or other adverse reactions to minocycline~* Prior exposure to neurotoxic chemotherapy~* Diagnosis of fibromyalgia~* Current or planned use of methoxyflurane, oral contraceptives, isotretinoin, penicillin, or ergot alkaloids~* History of allergic or other adverse reactions to tetracycline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (minocycline hydrochloride) (Type: EXPERIMENTAL): Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
- Arm II (placebo) (Type: PLACEBO_COMPARATOR): Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).